Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives
Clinical and Translational Medicine · 2026-06 · 16 (6)
DOI: 10.1002/ctm2.70720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 15.06.2026. Verfasst von Ziliang Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, PR China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Precision Medicine, Neoplasms, Gene Editing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Inducible CRISPR/Cas systems enable spatiotemporal control of genome editing in response to chemical, optical, biological, or physical stimuli. By restricting genome‐editing activity to defined conditions, these systems may reduce off‐target exposure and immune burden while improving tumor‐selective control, making them attractive tools for precision oncology. Main body This review summarizes the molecular mechanisms, design principles, and current applications of inducible CRISPR/Cas systems in cancer research and therapy. These platforms are classified into chemically inducible, optogenetic, tumor microenvironment‐responsive, physically triggered, and logic‐gated systems. Regulatory strategies are discussed at multiple levels, including transcriptional control, post‐translational regulation, guide RNA engineering, and stimulus‐responsive delivery. Key applications include functional genomic screening, cancer modeling, therapeutic gene editing, immunotherapy enhancement, and combinatorial treatment strategies. We also examine current delivery approaches, including viral vectors, lipid nanoparticles, stimulus‐responsive nanocarriers, and biomimetic platforms.
Conclusion
Inducible CRISPR/Cas systems represent a promising platform for next‐generation precision cancer therapy. However, substantial optimization and rigorous preclinical validation remain necessary to address challenges related to leaky expression, induction efficiency, tissue penetration, immunogenicity, and long‐term safety before clinical translation can be realized. Key points Inducible CRISPR/Cas systems enable conditional genome editing in precision oncology. Chemical, optical, TME‐responsive, physical, and logic‐gated systems offer distinct control features. Delivery, leakiness, immunogenicity, and safety remain key translational barriers. Ex vivo immune‐cell engineering and locoregional delivery may offer nearer‐term clinical routes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thyroid Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, PR China.
ORCID-Profile: Yong Han
Zitieren
APA
Ding, Z., Wei, Y., Han, Y., & Gu, P. (2026). Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives. Clinical and Translational Medicine, 16(6). https://doi.org/10.1002/ctm2.70720
Vancouver
Ding Z, Wei Y, Han Y, Gu P. Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives. Clinical and Translational Medicine. 2026;16(6). doi:10.1002/ctm2.70720
BibTeX
@article{Ding2026,
author = {Ding, Ziliang and Wei, Yukun and Han, Yong and Gu, Pengfei},
title = {Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {6},
doi = {10.1002/ctm2.70720}
}
EUVIMED